

[Commissioner of Patents and Trademarks]

A7 supernatants. The monoclonal anti-CD42a (AN51, IgG<sub>2a</sub> k) was obtained from Dako Diagnostics (Mississauga, ON). The control murine IgG was purchased from Cedarlane (Hornby, ON).

**IN THE CLAIMS**

Please amend claims 1, 2, 3, 4 and 5 as set forth below.

**Claim 1 (Amended)**

B2 A method for inhibiting HLA alloimmune response to platelet transfusion, said method comprising the step of presensitizing platelets with at least one monoclonal antibody against HLA, a portion thereof or β2-microglobulin, wherein said platelets if administered to a patient prevent an HLA alloimmune response in said patient.

A8

**[Claim 2 (Amended)]**

The method of claim 1, wherein said at least one monoclonal antibody is selected from W6/32, L368, or MA2.1.

**[Claim 3 (Amended)]**

A method for inhibiting an HLA alloimmune response to platelet transfusion, said method comprising the steps of:

- a) presensitizing platelets with at least one monoclonal antibody against HLA, a portion thereof or β2-microglobulin;
- b) transfusing the presensitized platelets of step a) into a patient, said presensitized platelets inhibiting an HLA alloimmune response in said patient.

[Commissioner of Patents and Trademarks]

[Claim 4 (Amended)]

The method of claim 3, wherein said HLA alloimmune response is still inhibited after at least two transfusions into said patient.

A8

[Claim 5 (Amended)]

A method for inhibiting refractoriness to subsequent transfusions in an alloimmunized patient, comprising the steps of:

- a) presensitizing platelets with at least one monoclonal antibody against HLA, a portion thereof or  $\beta 2$ -microglobulin; and
- b) transfusing the alloimmunized patient with the presensitized platelets of step a), the presensitized platelets preventing refractoriness to the transfusion.